These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 24861878)

  • 1. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
    Lo HW; Cao X; Zhu H; Ali-Osman F
    Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
    Senft C; Priester M; Polacin M; Schröder K; Seifert V; Kögel D; Weissenberger J
    J Neurooncol; 2011 Feb; 101(3):393-403. PubMed ID: 20589525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
    J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
    Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
    J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
    Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
    Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.
    Hou J; Lv A; Deng Q; Zhang G; Hu X; Cui H
    Oncol Rep; 2019 Feb; 41(2):753-764. PubMed ID: 30431125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
    Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
    Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway.
    Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X
    J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of glioma proliferation through allosteric inhibition of JAK2.
    He K; Qi Q; Chan CB; Xiao G; Liu X; Tucker-Burden C; Wang L; Mao H; Lu X; McDonald FE; Luo H; Fan QW; Weiss WA; Sun SY; Brat DJ; Ye K
    Sci Signal; 2013 Jul; 6(283):ra55. PubMed ID: 23838182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
    Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
    Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
    Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.